TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7746123

Group type: EXPERIMENTAL
Intervention: Short-term treatment (1 g of ciprofloxacin in a single daily dose for 2 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard treatment (1 g of ciprofloxacin in two daily doses for 5 days)
Number of subjects: 57
Study: 2643037

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 602

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily (with NSAIDs)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (with NSAIDs)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (with NSAIDs)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Omeprazole groups (overall)
Number of subjects: 602
Study: 1172813

Group type: EXPERIMENTAL
Intervention: Single daily dose of allopurinol (300 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Divided doses of allopurinol (100 mg three times a day)
Number of subjects: 20
Study: 31469508

Group type: EXPERIMENTAL
Intervention: Multidose drug dispensing (MDD)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Manual dispensing (Control)
Number of subjects: 179
Study: 31307833

Group type: EXPERIMENTAL
Intervention: CND 32 mg/RSV 20 mg
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: RSV 20 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: CND 32 mg
Number of subjects: 219
Study: 28578844

Group type: EXPERIMENTAL
Intervention: Dual-Mobility (DM) implant
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single-Bearing (SB) implant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy Controls (CTRLs)
Number of subjects: 24
Study: 26003019

Group type: EXPERIMENTAL
Intervention: Resolute Integrity zotarolimus-eluting stents
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Promus Element everolimus-eluting stents
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Both stents
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Chest pain after 12 months
Number of subjects: 1811
Study: 24085378

Group type: EXPERIMENTAL
Intervention: Group exercise therapy (90 min under physiotherapist guidance)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Home exercise therapy
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Group exercise therapy
Number of subjects: 209
Study: 21619618

Group type: EXPERIMENTAL
Intervention: First fitted amputees (FFA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: First fitted amputees (FFA) standing on the non-affected leg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Skilled prosthetic users (SPU)
Number of subjects: 28
Study: 19114852

Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etravirine 800 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care regimen
Number of subjects: 0
Study: 15575933

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily for 8 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (250 microg twice daily for 8 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast and Fluticasone
Number of subjects: 0
Study: 11874209

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 113
Study: 10460064

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg bolus, 9 mg/kg/h infusion for 1 hour)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (soybean emulsion, same volume as propofol)
Number of subjects: 24
Study: 7796591

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progesterone
Number of subjects: 0
Study: 2135834

Group type: EXPERIMENTAL
Intervention: Prednisone therapy (10 week course)
Number of subjects: 18
Study: 498955

Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy with splenectomy after multiple chemotherapy
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Chemotherapy producing complete clinical remission
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy with splenectomy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Clinical stage III patients
Number of subjects: 182
Study: 31868879

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical hysterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical hysterectomy followed by adjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodality strategy consisting of radical hysterectomy/perioperative chemotherapy
Number of subjects: 0
Study: 31095683

Group type: EXPERIMENTAL
Intervention: Self-administered individual treatment (SIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group treatment (GT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 28796687

Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25 suture
Number of subjects: 550

Group type: COMPARATOR
Intervention: Polyglactin 910 suture
Number of subjects: 550
Study: 26470422

Group type: EXPERIMENTAL
Intervention: Longidaze in addition to standard etiotropic antibacterial therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard etiotropic antibacterial therapy
Number of subjects: 0
Study: 23357198

Group type: EXPERIMENTAL
Intervention: 1×10(10) IU of the vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1×10(9) IU of the vaccine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1×10(8) IU of the vaccine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20689977

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Client-centered, supportive-experiential group therapy (SET)
Number of subjects: 174
Study: 19240109

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 87
Study: 17874015

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Breathing (IPPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Incentive Spirometry (IS)
Number of subjects: 40
Study: 15466071

Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.025-0.04 mg/kg per day) plus conventional therapy
Number of subjects: 8
Study: 11495269

Group type: EXPERIMENTAL
Intervention: Aerosol therapy (streptomycin and steroids)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 57
Study: 9692657

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg every other day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 23
Study: 7873824

Group type: EXPERIMENTAL
Intervention: Oral itraconazole 200 mg daily for 7 days
Number of subjects: 153

Group type: COMPARATOR
Intervention: Oral itraconazole 100 mg for 15 days
Number of subjects: 153
Study: 3145677

Group type: EXPERIMENTAL
Intervention: Carboprost (15‐methyl PGF2 alpha) administered 8 hours after ethacridine lactate instillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboprost (15‐methyl PGF2 alpha) administered 4 hours after ethacridine lactate instillation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carboprost (15‐methyl PGF2 alpha) administered 2 hours after ethacridine lactate instillation
Number of subjects: 0
Study: 31845611

Group type: EXPERIMENTAL
Intervention: EEGer neurofeedback software used for treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thought Technology Monastra‐Lubar Assessment Suite
Number of subjects: 0
Study: 30061276

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - single-fraction 24 Gy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT) - 30 Gy/10 fractions
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 55
Study: 27081177

Group type: EXPERIMENTAL
Intervention: pomalidomide + low-dose dexamethasone
Number of subjects: 447

Group type: COMPARATOR
Intervention: high-dose dexamethasone
Number of subjects: 447
Study: 25757358

Group type: EXPERIMENTAL
Intervention: Web-based psychotherapy
Number of subjects: 43
Study: 23747759

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg in very elderly patients
Number of subjects: 155

Group type: COMPARATOR
Intervention: Prasugrel 10 mg in nonelderly patients
Number of subjects: 155

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg in very elderly patients
Number of subjects: 155
Study: 20884923

Group type: EXPERIMENTAL
Intervention: 15 minutes application time
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 minutes application time
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One hour application time
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eight hours application time
Number of subjects: 60
Study: 18510659

Group type: EXPERIMENTAL
Intervention: tolterodine ER (4 mg) + tamsulosin (0.4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tamsulosin (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: tolterodine ER (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 15725881

Group type: EXPERIMENTAL
Intervention: Amniotic membrane graft (AMG) alone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Amniotic membrane graft (AMG) combined with intraoperative 0.025% mitomycin C
Number of subjects: 94
Study: 12466173

Group type: EXPERIMENTAL
Intervention: Macular buckling procedure
Number of subjects: 10
Study: 10620155

Group type: EXPERIMENTAL
Intervention: Pin-retained amalgam
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amalgam with a meta adhesive
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Composite resin with a beta-glass quartz insert
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Composite resin with a HEMA adhesive
Number of subjects: 32
Study: 7613636

Group type: EXPERIMENTAL
Intervention: Intervention group (screening)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall mortality analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Limited mortality analyses
Number of subjects: 0
Study: 2143596

Group type: EXPERIMENTAL
Intervention: Triatec 2.5 mg
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Triatec 5 mg
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Triatec 10 mg
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Combination of 20 mg Lasilix and Triatec 5 mg
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Overall treatment plan
Number of subjects: 770
Study: 7449282

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (normotensive patients)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 57
Study: 31715583

Group type: EXPERIMENTAL
Intervention: Feedback during small-sided games
Number of subjects: 20

Group type: COMPARATOR
Intervention: No feedback (control) during small-sided games
Number of subjects: 20
Study: 29993709

Group type: EXPERIMENTAL
Intervention: Fast Frequent Directions Algorithm with Sparse Subspace Embedding (SpEmb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fast Frequent Directions Algorithm
Number of subjects: 0
Study: 28783382

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 35
Study: 25596468

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (tirofiban infusion and coronary angiography within 6h)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Delayed invasive strategy (coronary angiography not advised within 6h)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Delayed invasive strategy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 170
Study: 23996046

Group type: EXPERIMENTAL
Intervention: Percutaneous short-segment pedicle screw internal fixation with PKP
Number of subjects: 43

Group type: COMPARATOR
Intervention: Simple PKP (control group)
Number of subjects: 43
Study: 21256149

Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI) - targeted print intervention by mail
Number of subjects: 1430

Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI) - targeted intervention and tailored message pages
Number of subjects: 1430

Group type: EXPERIMENTAL
Intervention: Tailored Intervention plus Phone (TIP) - targeted intervention, tailored message pages, and a telephone reminder
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1430
Study: 19380393

Group type: EXPERIMENTAL
Intervention: Endovascular abdominal aortic aneurysm repair (EVAR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open aneurysm repair (OAR)
Number of subjects: 0
Study: 17876916

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate pretreatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Suxamethonium without magnesium sulphate pretreatment
Number of subjects: 84
Study: 15052217

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 12079
Study: 12575397

Group type: EXPERIMENTAL
Intervention: Bitongxiao (BTX)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Jingfukang (JFK) granule (Control)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 11083217

Group type: EXPERIMENTAL
Intervention: Instruction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Passive observation
Number of subjects: 12
Study: 9192504

Group type: EXPERIMENTAL
Intervention: Subcutaneous salmon calcitonin (SCSCT) 50 IU/day for 30 days
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (INSCT) 200 IU/day for 30 days
Number of subjects: 204

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 204

Group type: COMPARATOR
Intervention: INSCT
Number of subjects: 204
Study: 1549989

Group type: EXPERIMENTAL
Intervention: Emergency medical system transport with prehospital 12-lead ECG
Number of subjects: 4

Group type: COMPARATOR
Intervention: Emergency medical system transport without prehospital ECG
Number of subjects: 4

Group type: COMPARATOR
Intervention: Local ambulance transport
Number of subjects: 4

Group type: COMPARATOR
Intervention: Private automobile transport (walk-in)
Number of subjects: 4
Study: 3905052

Group type: EXPERIMENTAL
Intervention: Medical treatment in low-risk tercile (VA population)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment in high-risk tercile (VA population)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment in CASS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical treatment in CASS
Number of subjects: 0
Study: 29329698

Group type: EXPERIMENTAL
Intervention: Combined exercise training (MS-EX) for 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (MS-C)
Number of subjects: 36
Study: 26896456

Group type: EXPERIMENTAL
Intervention: sarolaner (Simparica™) 2-4 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: afoxolaner (NexGard®) 2.5-6.8 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 24497345

Group type: EXPERIMENTAL
Intervention: CD133(+) BMC injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 60
Study: 22582693

Group type: EXPERIMENTAL
Intervention: Orienteering lessons for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Jogging training
Number of subjects: 20
Study: 20215545

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg once daily or 500 mg twice daily)
Number of subjects: 75
Study: 18831352

Group type: EXPERIMENTAL
Intervention: 2 mg/day buprenorphine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 4 mg/day buprenorphine
Number of subjects: 23
Study: 16019973

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine, LAAM, Methadone
Number of subjects: 0
Study: 11843073

Group type: EXPERIMENTAL
Intervention: Head injury
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Posttraumatic stress
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 82

Group type: COMPARATOR
Intervention: Orthopedic injury
Number of subjects: 82
Study: 10402974

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study: 7743739

Group type: EXPERIMENTAL
Intervention: Experimental questionnaires (specific questionnaires not detailed)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Patient preference scales
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Questionnaire on performance in various roles in life
Number of subjects: 97

Group type: COMPARATOR
Intervention: IRGL questionnaire
Number of subjects: 97
Study: 2103759

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg t.d.s.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 8
Study: 30897567

Group type: EXPERIMENTAL
Intervention: Power Point Therapy (PPT) - 10 units of 10 min each
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard physiotherapy - 10 units of 30 min each
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Power Point Therapy (PPT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 80
Study: 28940353

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 6000 mg/day for 28 days
Number of subjects: 8
Study: 27423164

Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (EX/RP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Open treatment following nonresponse to risperidone or placebo
Number of subjects: 70
Study: 25273659

Group type: EXPERIMENTAL
Intervention: No nasogastric intubation and early oral feeding (trial group)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Routine management (control group)
Number of subjects: 316
Study: 22886837

Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac 18.75 mg
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac 37.5 mg
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 20615225

Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting details of trial participants
Number of subjects: 345

Group type: COMPARATOR
Intervention: Chinese abstracts reporting control group intervention
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting number of participants randomized
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting benefits when interpreting trial results
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting trial design details
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Chinese abstracts defining primary outcome
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Chinese abstracts describing methods of random sequence generation
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting number of participants analyzed
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Percentage agreement in reporting between Chinese and English versions
Number of subjects: 345
Study: 18511049

Group type: EXPERIMENTAL
Intervention: Tegaserod with whole-dose PEG-E
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Tegaserod with split-dose PEG-E
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo with whole-dose PEG-E
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo with split-dose PEG-E
Number of subjects: 382

Group type: COMPARATOR
Intervention: Whole-dose PEG-E
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Split-dose PEG-E
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 382
Study: 21961341

Group type: COMPARATOR
Intervention: One insemination at 36 hours after hCG
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Two inseminations at 24 and 48 hours after hCG
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Patients with ovulatory dysfunction
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Patients with endometriosis
Number of subjects: 138
Study: 12534959

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Calcium gluconate/calcium carbonate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calcium supplements
Number of subjects: 15
Study: 10967229

Group type: EXPERIMENTAL
Intervention: Flashing red lights as elements with apparent movement as a unique cue in experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual frame surrounding letter stimuli in experiment 2
Number of subjects: 0
Study: 8872728

Group type: EXPERIMENTAL
Intervention: 10 mg of nitrendipine (Bypress; Bayer) 2 hours before SWL
Number of subjects: 20

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 20
Study: 1618486

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 91
Study: 6385259

Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m2 every 3 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg/m2 every 3 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Doxorubicin or Mitoxantrone (as secondary therapy)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 59